Affimed Therapeutics is a clinical-stage biopharmaceutical company from Heidelberg (Germany) which is developing highly targeted cancer immunotherapies for some leukemias and Hodgkin’s Lymphoma. An undisclosed shareholder has just increased its position in the company by purchasing an additional 3.3 million shares, leading to a total of €19.2M private investment.
Affimed Therapeutics is a NASDAQ-listed biotech which is trialling immunotherapies for cancers such as Hodgkin’s Lymphoma. Affimed’s candidates are being developed in the field of immuno-oncology, which broadly looks to innovate new monoclonal antibody types to stimulate an immune response against tumor cells.
Affimed’s proprietary next-generation antibodies are bi-specific (binding to multiple target sites at once), and are so-called TandAbs due to their tandem structure. TandAbs are designed to direct and establish a bridge between either NK-cells or T-cells with the tumor cells, in order to trigger a signal cascade that leads to the destruction of cancerous types.
Affimed’s leading candidate, AFM13, is in phase II trials for Hodgkin’s lymphoma,